2018 International Congress » Parkinson's Disease: Cognition

Date: Monday, October 8, 2018

Time: 1:15pm-2:45pm

Location: Hall 3FG

Meeting: 2018 International Congress

1:15pm-2:45pm: A bayesian network approach for prediction of future dementia in Parkinson’s disease

P. Surathi, M. Mirian, K. Sundvick, S. Appel-Cresswell, M. McKeown (Vancouver, BC, Canada)

1:15pm-2:45pm: A promising model for cognitive dysfunction in Parkinson’s Disease by AAV-mediated alpha-synuclein overexpression in hippocampus

E. Cinar, G. Yalcin-Cakmakli, E. Saka, A. Ulusoy, B. Tel, B. Elibol (Ankara, Turkey)

1:15pm-2:45pm: Affective Theory of Mind Impaired in Parkinson’s Disease: Negative- and Neutral- specific impairments of Emotion State Decoding

C.H. Tan, S.C. Tu, R.L. Yu (Kaohsiung, Taiwan)

1:15pm-2:45pm: Agreement Between Patients and Informants on the Penn Parkinson’s Daily Activity Questionnaire

B. Deck, S. Xie, J. Rick, A. Chen-Plotkin, J. Duda, J. Morley, N. Dahodwala, J. Trojanowski, D. Weintraub (Philadelphia, PA, USA)

1:15pm-2:45pm: Alzheimer’s Disease Genetic Risk Variants Predict Cognitive Decline in Parkinson’s Disease

T. Tropea, K. Maddy, J. Rick, J. Trojanowkski, D. Weintraub, A. Chen-Plotkin (Philadelphia, PA, USA)

1:15pm-2:45pm: Amyloid deposition affects cognitive manifestations in Parkinson’s disease: The PPMI dataset

E. Fiorenzato, R. Biundo, D. Cecchin, AC. Frigo, L. Weis, J. Kim, A. Strafella, A. Antonini (Venice, Italy)

1:15pm-2:45pm: An analysis of cortical thickness in early Parkinson’s disease patients with cognitive impairment

M. Mei, K. Nie, Y. Gao, Y. Zhang, L. Wang (Guangzhou, China)

1:15pm-2:45pm: An investigation of the relationship between computational neuropsychological testing outcomes and symptoms of Parkinson’s disease

L. Jiang, Y. Zhu, Z. Ye, Z. Pei, L. Chen (Guangzhou, China)

1:15pm-2:45pm: Biomarkers of rapid progression of cognitive decline in Parkinson’s disease

S. Martinez-Horta, F. Sampedro, J. Pagonabarraga, J. Marin-Lahoz, A. Horta-Barba, H. Bejr-Kasem, I. Aracil, J. Perez-Perez, MA. Boti, J. Kulisevsky. (Barcelona, Spain)

1:15pm-2:45pm: Brain Mechanisms of Associative Memory Deficits in Parkinson’s Disease without Dementia

T. Alrazi, J. Cheetham, L. Derwent, A. Hanganu, T. Hammer, I. Kathol, M. Kibreab, S. Lang, N. Ouellet, J. Provost, M. Ramezani, J. Sarna, E. Yoon, O. Monchi (Calgary, AB, Canada)

1:15pm-2:45pm: Cerebellar tDCS modulates negative emotions recognition in Parkinson’s disease

F. Ruggiero, F. Cortese, M. Nigro, T. Bocci, L. Borellini, M. Vergari, F. Mameli, A. Priori, R. Ferrucci (Milano, Italy)

1:15pm-2:45pm: Change of Cognition Functions after Subthalamic Nucleus-Deep Brain Stimulationin in Parkinson’s Disease

L. Wu, L. Chen (Guangzhou, China)

1:15pm-2:45pm: Characteristics in relation to demographic, disease related and clinical variables of a cohort of Parkinson’s disease patients from Northern Sri Lanka

A. Keshavaraj, S. Kunathilagam (Jaffna, Sri Lanka)

1:15pm-2:45pm: Clinical predictors of screen-defined dementia in early Parkinson’s

F. Baig, M. Lawton, M. Rolinski, C. Ruffmann, T. Barber, J. Klein, C. Lo, Y. Ben-Shlomo, M. Hu (Oxford, United Kingdom)

1:15pm-2:45pm: Cognitive function is associated with Balance in Parkinson Disease: Cross-sectional study in Cali-Colombia

B. Munoz, J. Orozco, J. Valderrama, A. Navarro, Y. Castaño, J. Arango (Cali, Colombia)

1:15pm-2:45pm: Cognitive Impairment and Depression in Patients with Parkinson’s Disease

XD. Qu, SS. Li (Lanzhou, China)

1:15pm-2:45pm: Curcumin improves cognitive function in rotenone-induced rat model of Parkinson’s disease (PD)

S. Madiha, S. Haider (Karachi, Pakistan)

1:15pm-2:45pm: Depressive symptoms effect subjective sleep quality in Parkinson’s Disease with and or without cognitive disturbance

J. Zhu, L. Zhang (Nanjing, China)

1:15pm-2:45pm: Diagnostic accuracy and imaging correlates of the Free and Cued Selective Reminding Test for screening mild cognitive impairment in Parkinson’s disease

J. Pagonabarraga, A. Horta-Barba, J. Marín-Lahoz, S. Martinez-Horta, H. Bejr-Kasem, I. Aracil, J. Pérez-Pérez, B. Pascual-Sedano, J. Kulisevsky (Barcelona, Spain)

1:15pm-2:45pm: Distinct networks contribute to the dysexecutive and posterior cortical cognitive syndromes of cognitive impairment in Parkinson’s Disease

S. Lang, S. Jobert, B. Mejia-Constain, C. Degroot, A. Lafontaine, A. Hanganu, P. Bellec, O. Monchi (Calgary, AB, Canada)

1:15pm-2:45pm: Dual task walking differentially affects toe clearance in Lewy body disease: A contributor to dynamic falls risk?

L. Alcock, R. McArdle, L. Aubrook, B. Galna, A. Thomas, L. Rochester (Newcastle upon Tyne, United Kingdom)

1:15pm-2:45pm: Effect of different normative samples and cut-off values on determination of cognitive impairment in the Parkinson’s Progression Marker Initiative

K. Wyman-Chick, D. Weintraub, P. Martin, L. Erickson, M. (Saint Paul, MN, USA)

1:15pm-2:45pm: Effect of Glucocerebrosidase enzymatic activity on neural activation during a cognitive task in Parkinson’s disease patients

M. Ramezani, J.S. Provost, N. Auclair-Ouellet, I. Kathol, A. Hanganu, M. Kibreab, J. Cheetham, T. Hammer, L. Derwent, A. Robichaud, R. Chiang, J. Sarna, SP. Sardi, O. Monchi (Calgary, AB, Canada)

1:15pm-2:45pm: Effect of striatal dopamine depletion on cognition in de novo Parkinson’s disease

H. Jeong, S. Chung, J. Oh, J. Kim, P. Lee (Seoul, Republic of Korea)

1:15pm-2:45pm: Effective Tools for Mild Cognitive Impairment Level I Criteria of Movement Disorder Society: Utility of Screening Tests and Their Interconversion

RL. Yu, WJ. Lee, JY. Li, YY. Chang, CC. Chen, JJ. Lin, YF. Sung, TK. Lin, RS. Chen, YH. Yang, YW. Yang, SJ. Wang, JL. Hsu, HC. Wang, JL. Fuh (Tainan, Taiwan)

1:15pm-2:45pm: Effects of computerized cognitive training, with and without concurrent exercise, on executive functions in Parkinson’s disease

M. Fernandez-del-Olmo, JA. Sánchez-Molina, H. Fernandez-Lago, L. Morenilla-Burlo, J. Gómez-Varela, N. Fogelson (A Coruña, Spain)

1:15pm-2:45pm: Effects of orthostatic hypotension and supine hypertension on cognition in Parkinson’s disease

H. Jeong (Changwon, Republic of Korea)

1:15pm-2:45pm: Epidemiological risk factors on cognition with PD patients in male: A cross-sectional study from southwest of China

Y. Wu, RW. Ou, H. Liu, QQ. Wei, XJ. Gu, Q. Han, LY. Zhang, W. Song, B. Cao, YP. Chen, B. Zhao, HF. Shang (Chengdu, China)

1:15pm-2:45pm: Evaluation of the Loneliness among the Caregivers of Parkinson Disease Dementia

M. Gultekin, A. Ekinci (Kayseri, Turkey)

1:15pm-2:45pm: Exploring the relationship between motor impairment, vascular burden and cognition in Parkinson’s disease

T. Stojkovic, E. Stefanova, I. Soldatovic, V. Markovic, I. Stankovic, F. Agosta, I. Petrovic, S. Galantucci, M. Filippi, V. Kostic (Belgrade, Serbia)

1:15pm-2:45pm: Eye Movements during Reading in Parkinson’s Disease: A Pilot Study

J. Waldthaler, P. Tsitsi, G. Öqvist Seimyr, M. Nilsson Benfatto, P. Svenningsson (Marburg, Germany)

1:15pm-2:45pm: Feasibility of a health game on cognition in Parkinson’s disease: Interim analyses of the Parkin’Play Study

S. vd Weijer, M. Kuijf, A. Duits, R. Kessels, N. de Vries, S. Köhler, G. Tissingh, B. Bloem (Maastricht, Netherlands)

1:15pm-2:45pm: Fluvoxamine maleate effects on dopamine signaling in the prefrontal cortex of stressed parkinsonian rats: Implications for learning and memory

E. Dalle, W. Daniels, M. Mabandla (Durban, South Africa)

1:15pm-2:45pm: Frontal midline theta activity is reduced during cognitive control in Parkinson’s disease

A. Singh, S. Richardson, N. Narayanan, J. Cavanagh (Iowa City, IA, USA)

1:15pm-2:45pm: Hypertriglyceridemia is associated with Parkinson disease mild cognitive impairment (PD-MCI)

S. Ng, KY. Tay, X. Huang, NSY. Chia, S. Archaryya, F. Setiawan, ZH. Lu, J. Tan, YL. Ng, MC. Wen, A. Ng, W. Au, EK. Tan, L. Tan (Singapore, Singapore)

1:15pm-2:45pm: Meta-Analysis of Short-afferent inhibition and Cognitive Impairment in Parkinson’s Disease

J.F. Martin-Rodriguez, P. Mir (Seville, Spain)

1:15pm-2:45pm: Multi-limb dual-task cost in Parkinson disease: Evaluating effects of implicit and explicit cues

T. McIsaac, R. Cohen, R. Bay, J. Gupta, C. Adler (Mesa, AZ, USA)

1:15pm-2:45pm: Neurocognitive outcomes of STN-DBS in patients with Parkinson’s disease: A 10-year review of local experiences in Hong Kong

V. Tang, X.L. Zhu, D. Chan, C. Lau, A. Chan, V. Mok, J. Yeung, W.S. Poon (Hong Kong)

1:15pm-2:45pm: Neuroprotective potential of curcumin in combination with piperine against 6-hydroxy dopamine induced motor deficit and neurochemical alterations in rats

S. Singh (Moga, India)

1:15pm-2:45pm: Neuropsychological and clinical assessment for the differential diagnosis of patients with PDD vs. DLB

E. Fiorenzato, L. Weis, V. Camparini, F. Pistonesi, R. Schifano, E. Gasparoli, A. Antonini, R. Biundo (Venice, Italy)

1:15pm-2:45pm: Neuropsychological Assessment of Cognitive Dysfunction in Parkinson’s Disease: A Comparison of Four Screening Instruments

S. Schnitzler, L. Flitsch, S. Kaesberg, J. Kessler, E. Kalbe, M. Barbe (Cologne, Germany)

1:15pm-2:45pm: Neuropsychological Evaluation of a Vietnamese-speaking Man with Parkinson’s Disease and Consideration for Deep Brain Stimulation Surgery: A Case Report

B. Tran, K. Lawler (Philadelphia, PA, USA)

1:15pm-2:45pm: Olfactory impairment correlates strongly with limbic blood flow in patients with Parkinson’s disease

K. Ohta, T. Nakajima (Niigata, Japan)

1:15pm-2:45pm: Opposite effects of dopamine on specific NoGo perfomance in young and late onset Parkinson’s disease and the relationship to nigrostriatal degeneration

D. Kübler, H. Schroll, U. Scheller, R. Buchert, A. Kühn (Berlin, Germany)

1:15pm-2:45pm: Performance of Parkinson´s disease cognitive scale rating scale (PD-CRS) after subthalamic nucleus deep brain stimulation. Comparison with Mattis Dementia Rating Scale (MDRS) and Mini-Mental State Examination (MMSE)

C. García-Sánchez, B. Pascual-Sedano, A. Gironell, R. Rodriguez, J. Pagonabarraga-Mora, J. Marin-Lahoz, J. Pérez-Perez, A. Campolongo, C. izquierdo, H. Bejr-Kasen, I. Aracil, S. Martínez -Horta, A. Horta, M. Botí, E. Marin, J. Kulisevsky (Barcelona, Spain)

1:15pm-2:45pm: Plasma levels of vitamin D in patients with Parkinson’s disease: Correlation with Mini Mental State Examination and disease duration

M. Barichella, L. Lorio, C. Bolliri, A. Giana, V. Ferri, G. Pinelli, E. Cassani, S. Caronni, C. Esposito, G. Riboldazzi, A. Maras, A. Perretti, F. Del Sorbo, P. Amadeo, R. Cilia, E. Cereda, G. Pezzoli (Milan, Italy)

1:15pm-2:45pm: Predictive factors of fast cognitive decline in Parkinson’s disease after subthalamic stimulation: Myth or reality?

F. Fluchere, F. Ory-Magne, M. Anheim, V. Rousseau, A. Eusebio, O. Lagha Boukbiza, B. Lemesle, T. Witjas, N. Longato, C. Tranchant, C. Brefel-Courbon, JP. Azulay (Marseille, France)

1:15pm-2:45pm: Relationship between dopaminergic asymmetric degeneration and attentional resources in Parkinson’s disease

P. Ortelli, D. Ferrazzoli, V. Cian, L. Caremani, G. Madeo, G. Palamara, R. Maestri, G. Frazzitta (Gravedona ed Uniti, Italy)

1:15pm-2:45pm: Reproductive factors influence on cognitive function of Parkinson’s disease in female patients-from a cross-sectional study

Y. Wu, H. Liu, R.W. Ou, Q.Q. Wei, H.F. Shang (Chengdu, People’s Republic of China)

1:15pm-2:45pm: Resting-state fMRI in Parkinson’s disease patients with cognitive impairment: A meta-analysis

A. Wolters, S. vd Weijer, A. Leentjens, A. Duits, H. Jacobs, M. Kuijf (Maastricht, Netherlands)

1:15pm-2:45pm: Rivastigmine solution in the one-year treatment of Parkinson’s disease dementia and dementia with Lewy bodies

P.Y. Chiu (Changhua, Taiwan)

1:15pm-2:45pm: Role of Sex on Cholinergic Activity and Attention in Parkinson’s disease

D. Martini, R. Morris, T. Madhyastha, T. Grabowski, J. Quinn, F. Horak (Portland, OR, USA)

1:15pm-2:45pm: Selection of antiparkinson drug and cognition in Japanese Parkinson Disease patients

K. Konaka, Y. Kajiyama, R. Gajanan, M. Mihara, N. Hattori, H. Mochizuki (Suita, Japan)

1:15pm-2:45pm: Sex Differences in Cognitive Performance in De-Novo Parkinson’s Disease

S. Banks, E. Bayram, J. Kaylegian, B. Bluett (Las Vegas, NV, USA)

1:15pm-2:45pm: Social interaction and Cognition in patients with Parkinson’s disease

A. Kumon, M. Sagawa, M. Saruwatari, N. Kawashima, K. Hasegawa (Sagamihara, Japan)

1:15pm-2:45pm: Study on Correlation between Serum Vitamin D Level and Cognition of Parkinson’s Disease

XY. Xu, J. Qian, XS. Huang, SY. Tian, D. Tong (Dalian, China)

1:15pm-2:45pm: Subcortical and Cortical 123I-FP-CIT binding deficits and mild cognitive impairment in Parkinson’s disease

A. Pilotto, F. Schiano DiCola, E. Premi, V. Garibotto, A. Scalvini, R. Turrone, R. Grasso, B. Bigni, S. Gipponi, B. Paghera, MC. Rizzetti, b. Borroni, A. Padovani (Brescia, Italy)

1:15pm-2:45pm: The analysis of cognitive impairment associated with Parkinson’s disease

Z. Mao, X. Xue (Hubei, China)

1:15pm-2:45pm: The Association Between Inhibitory Control and Freezing of Gait Severity in Parkinson’s Disease

E. Bayram, S. Banks, J. Longhurst, B. Bluett (Las Vegas, NV, USA)

1:15pm-2:45pm: The clinical characteristics and cognitive features of mild cognitive impairment in Parkinson’s disease and analysis of relevant factors

K. Nie, Y. Gao, M. Mei, M. Guo, Z. Huang, L. Wang, J. Zhao, Y. Zhang, L. Wang (Guangzhou, China)

1:15pm-2:45pm: The comparison of three brief cognitive tests for diagnosing mild cognitive impairment in newly diagnosed Parkinson’s disease

S. Kim, J. Jung, D. Seog (Busan, Republic of Korea)

1:15pm-2:45pm: The development of an instrument for measuring Parkinson’s patient empowerment

P. Viwattanakulvanid (Bangkok, Thailand)

1:15pm-2:45pm: The effects of sensory reward cues on risky decision making in Parkinson’s disease

M. Cherkasova, P. Surathi, S. Yeung, AJ. Stoessl, M. McKeown, S. Appel-Cresswell, C. Winstanley, J. Barton (Vancouver, BC, Canada)

1:15pm-2:45pm: The Portuguese Version of Montreal Cognitive Assessment as a screening test comparing Vascular Parkinsonism and Parkinson´s Disease in a hospital cross-section study

A. Velon, M. Mendes, R. Almendra, A. Almeida, M. Correia, C. (Vila Real, Portugal)

1:15pm-2:45pm: The relationship between asymmetric dopamine loss and cognition in early Parkinson’s disease patients from PPMI study

R. Biundo, E. Fiorenzato, L. Weis, A. Antonini (Venice, Italy)

1:15pm-2:45pm: Transcranial magnetic stimulation increases cognition globally and longitudinally in Parkinson’s disease

J. Trung, A. Hanganu, S. Jobert, C. Degroot, B. Mejia-Constain, M.A. Bruneau, A.L. Lafontaine, Q.P.N. Clinicians, A. Strafella, O. Monchi (Montréal, QC, Canada)

1:15pm-2:45pm: Turning during gait is associated with gray matter density of the nucleus basalis of Meynert in Parkinson’s disease

R. Morris, T. Madhyastha, D. Martini, K. Smulders, J. Quinn, V. Kelly, K. Edwards, C. Zabetian, T. Grabowski, F. Horak (Portland, OR, USA)

1:15pm-2:45pm: Using Vision to Predict Dementia in Parkinson’s Disease

L-A. Leyland, R. Mahmood, S. Hewitt, M. Durteste, F. Bremner, M. Lai, L. Miller, A. Saygin, C. Song, P. Keane, A. Schrag, R. Weil (London, United Kingdom)

1:15pm-2:45pm: Working memory maintenance and manipulation in Parkinson’s disease: An fMRI study

K. Giehl, A. Ophey, J. Hammes, S. Rehberg, C. Eggers, T. Lichtenstein, D. Maintz, E. Kalbe, T. van Eimeren (Cologne, Germany)

« View all sessions from the 2018 International Congress.